ClinicalTrials.gg
RecruitingNCT06776172Updated Jul 3, 2025

Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.

An interventional study of Extended Pelvic Lymph Node Dissection in Prostate Cancer Surgery and Prostate Cancers, sponsored by University Hospital, Basel, Switzerland. Recruiting at 15 sites in Switzerland. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 136 studies in Prostatic Neoplasms with a site in Switzerland — 40 open to participants now, 58 under way, 20 of them phase 3. Prostatic Neoplasms · Switzerland.

Planned enrollment
35th of 107
400 · median 140
Started
2025
with 8 others
No phase
23 of 136
8 open now
Primary completion
2027-02
later than 21 of 57 live
Registered
114th of 136
by date
Lead sponsor
7 of 136
University Hospital, Basel, Switzerland

Among the 136 studies in Prostatic Neoplasms with a site in Switzerland, this one is the 35th largest by planned enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2025, is one of 23 with no phase, reaches primary completion later than 21 of the 57 other live ones, and was the 114th registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

40 of the 136 studies in Prostatic Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:

34 more — sign in →

All 40 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Prostatic Neoplasms with a site in Switzerland, or all of them as a file.
02

Study summary

The aim of the DISSECTION 2.0 study is to determine whether extended pelvic lymph node dissection (ePLND) provides a therapeutic benefit for high-risk prostate cancer patients by improving cancer staging and potentially removing micrometastatic disease, ultimately improving their outcomes.

Read the detailed description

Prostate cancer is the second most common cancer in men globally and a major cause of cancer deaths in Europe. For men with localized prostate cancer (PCa) and a life expectancy of over 10 years, radical prostatectomy (RP) is the standard treatment. It improves survival compared to conservative management. However, there is debate about de benefit of pelvic lymph node dissection (PLND), the removal of lymph nodes in the pelvis, during RP. While PLND can be omitted in low risk PCa patients, extended PLND (ePLND) is recommended in PCa patients at high-risk for recurrence in order to improve nodal staging The DISSECTION 2.0 study aims to investigate whether extended PLND (ePLND) provides additional benefits for men with high-risk PCa. The hypothesis is that ePLND might help by removing undetectable cancer cells (micrometastases) in the lymph nodes or by better staging the disease for treatment planning. While imaging techniques like PSMA-PET are good at detecting cancer spread, they still miss approximately 60% of cancer-bearing lymph nodes, leaving room for ePLND to potentially improve outcomes.

ePLND involves removing more lymph nodes than standard PLND, leading to better detection of cancer spread. However, it also increases surgery time and complications slightly, though serious complications are rare.

03

Conditions studied

  • Prostate Cancer Surgery
  • Prostate Cancers

Browse trials for

Keywords

  • Pelvic Lymph Node Dissection
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years and >15 years
  • Any -proven WHO/ISUP grade groups III-V PCa
  • High-risk prostate cancer defined as:

    • Any biopsy-proven WHO/ISUP grade group III-V PCa or
    • ISUP grade group II and PSA > 20 ng/ml
  • PSMA-PET: negative staging for regional and distant
  • multidisciplinary tumorboard recommendation for radical prostatectomy
  • 0-1
  • Adequate condition (ASA ≤ III) for general anesthesia and RP

Exclusion criteria

Exclusion Criteria:

  • ISUP grade group I PCa and cT1 or cT2 (MRI)
  • cT4 (MRI) PCa
  • PSMA-PET: positive staging for local and distant
  • Any prior , local or systemic treatment for PCa
  • Previous PLND or pelvic radiotherapy
  • Patients with a prior and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence.
  • Any other serious underlying medical, psychiatric, psychological, familial, or geographical
  • condition, which in the judgment of the investigator may interfere with the planned
  • staging, treatment and follow-up, which affect patient compliance or place the patient at
  • high risk from treatment-related complications.
  • Vulnerable men (participants incapable of judgment or participants under tutelage) will not be included in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Radical prostatectomy with extended pelvic lymph node dissection

    Procedure: Extended Pelvic Lymph Node Dissection

  • No intervention
    Radical prostatectomy without extended pelvic lymph node dissection

Interventions

  • ProcedureExtended Pelvic Lymph Node Dissection

    Extended pelvic lymph node dissection during radical prostatectomy

    Also known as: Extended Lymph Node Dissection

06

What researchers measure

Primary outcomes

  1. Prostate specific antigen (PSA) persistence

    defined as failure to reach a PSA value of \<0.1 ng/ml

    Time frame: 3 month (+/- 2 weeks) postoperatively

  2. Biochemical recurrence free survival (BCRFS)

    time from randomization to biochemical recurrence, defined as serum PSA level ≥ 0.2 ng/ml

    Time frame: within 24 months post surgery

Secondary outcomes

  1. PSA persistence (PSAP) above detection limit

    cut-off ≥ 0.03 ng/ml

    Time frame: postoperative to the end of the study at 10-15 years

  2. Initiation time of adjuvant or salvage therapies

    Calculated from randomization to the start of any adjuvant or salvage therapy. Salvage radiotherapy (SRT) to the prostatic fossa only excluding lymphatics and without androgen deprivation therapy) will not count as an event for this endpoint if: * A PSMA-PET-computed tomography prior to SRT was negative for disease beyond the prostatic fossa, and * the SRT led to a PSA \<0.1 ng/ml (PSAP) or ≤ 0.2 ng/ml (biochemical recurrence-free survival, BCRFS), respectively.

    Time frame: postoperative to the end of the study at 10-15 years

  3. Time to loco-regional recurrence

    Calculated from randomization until the first local (prostate bed) or regional (within the extent of the ePLND template) recurrence.

    Time frame: from randomization to end of study at 10-15 years

  4. Localization of progression

    Prostate-specific membrane antigen positron emission tomography (PSMA-PET)

    Time frame: from randomization to end of study at 10-15 years

  5. Time to distant metastasis

    Calculated from randomization until the first occurrence of distant metastasis.

    Time frame: postoperative to the end of the study at 10-15 years

  6. Prostate cancer-specific survival

    death due to prostate cancer

    Time frame: postoperative to the end of the study at 10-15 years

  7. Overall survival

    death from any cause

    Time frame: postoperative to the end of the study at 10-15 years

  8. Intraoperative complications

    Documented using the CLASSintra classification

    Time frame: during surgery

  9. Postoperative complications

    Assessed using the Clavien-Dindo classification

    Time frame: postoperative up to 10-15 years

  10. Adverse events (AEs) related to ePLND

    Categorized according to CTCAE version 5.0

    Time frame: postoperative up to 10-15 years

  11. Patient-reported outcome measures (PROMs)

    tracked using the Expanded Prostate Cancer Index Composite (EPIC)-26 questionnaire Score 1-100 (100 indicates best quality of life score)

    Time frame: postoperative up to 10-15 years

Other outcomes

  1. Evaluation of risk prediction for nodal invasion

    from prostate biopsy results

    Time frame: postoperative to the end of the study at 10-15 years

  2. Evaluation of the potential value of unilateral ePLND

    Time frame: postoperative to the end of the study at 10-15 years

07

Study locations

15 of 15 sites recruiting
  • Cantonal Hospital Aarau
    Aarau, Switzerland
    Recruiting
    • Lukas Prause, Dr · Contacturo@ksa.ch · +41 62 838 47 36
    • Lukas Prause, Dr. · Principal investigator
    • Rainer Grobholz, Prof. · Sub investigator
  • University Hospital Basel
    Basel, 4031, Switzerland
    Recruiting
    • Cyrill Rentsch, Prof. Dr. med. · Contactcyrill.rentsch@usb.ch · +41 61 2687122
    • Helge Seifert, Prof. · Sub investigator
    • Cyrill Rentsch, Prof. Dr. med. · Principal investigator
    • Christian Engesser, Dr. · Sub investigator
    • Alexandros Papachristofilou, Dr. · Sub investigator
    • Guillaume Nicolas, Dr. · Sub investigator
  • Inselspital
    Bern, Switzerland
    Recruiting
    • Beat Roth, Prof. Dr. · Contactbeat.roth@insel.ch · +41 31 63 2 36 64
    • Beat Roth, Prof. Dr. · Principal investigator
  • Lindenhof Hospital
    Bern, Switzerland
    Recruiting
    • Silvan Boxler, Dr · Contactsilvan.boxler@hin.ch · +41 31 300 38 88
    • Silvan Boxler, Dr. · Principal investigator
  • Cantonal Hospital Biel
    Biel, Switzerland
    Recruiting
    • Roland Seiler-Blarer, Prof · Contacturologie@szb-chb.ch · +41 32 324 32 06
    • Roland Seiler-Blarer, Prof. · Principal investigator
  • Cantonal Hospital Chur
    Chur, Switzerland
    Recruiting
    • Räto Strebel, PD. Dr. · Contacturologie@ksgr.ch · +41 81 256 62 37
    • Räto Strebel, PD. Dr. · Principal investigator
    • Richard Cathomas, Prof. Dr. · Sub investigator
  • University Hospital Geneva
    Geneva, Switzerland
    Recruiting
    • Massimo Valerio, Prof. Dr. · Contactsecretariat.urologie@hug.ch · +41 (0)22 372 79 53
    • Massimo Valerio, Prof. Dr. · Principal investigator
  • Centre hospitalier universitaire vaudois (CHUV)
    Lausanne, Switzerland
    Recruiting
    • Ilaria Lucca, PD. Dr. · ContactIlaria.Lucca@unil.ch · +41 21 314 2981
    • Ilaria Lucca, PD. Dr. · Principal investigator
  • Cantonal Hospital Liestal
    Liestal, 4410, Switzerland
    Recruiting
    • Svetozar Subotic, Dr · Contactsvetozar.subotic@ksbl.ch · +41 61 400 21 72
    • Svetozar Subotic, Dr. · Principal investigator
  • Cantonal Hospital Luzern
    Lucerne, Switzerland
    Recruiting
    • Christian Fankhauser, Prof. Dr. · Contactinfo.urologie@luks.ch · +41 41 205 45 10
    • Christian Fankhauser, Prof. Dr. · Principal investigator
  • Ospedale Regionale di Lugano
    Lugano, Switzerland
    Recruiting
  • Cantonal Hospital Neuchâtel
    Neuchâtel, Switzerland
    Recruiting
    • Daniel Nguyen, PD. Dr. · Contacturologie@rhne.ch · +41 327133514
    • Daniel Nguyen, PD. Dr. · Principal investigator
  • Cantonal Hospital St. Gallen
    Sankt Gallen, Switzerland
    Recruiting
    • Daniel Engeler, Prof. Dr. · Contactbeckenbodenzentrum@kssg.ch · +41 71 494 30 01
    • Daniel Engeler, Prof. Dr. · Principal investigator
  • Hospital Triemli, Zürich
    Zurich, Switzerland
    Recruiting
  • University Hospital Zürich
    Zurich, Switzerland
    Recruiting
    • Ashkan Mortezavi, PD. Dr. · Contactashkan.mortezavi@usz.ch · +41 44 255 54 40
    • Ashkan Mortezavi, PD. Dr. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 24 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2025
First posted
Jan 15, 2025
StartActual
Feb 10, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2040
Last update
Jul 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06776172
Responsible party
Sponsor
First posted
Jan 15, 2025
Start date
Feb 10, 2025
Primary completion
Feb 2027 (estimated)
Completion
Feb 2040 (estimated)
Last update
Jul 3, 2025

Study contacts

Cyrill Rentsch, Prof. Dr. med.
Contact
cyrill.rentsch@usb.ch
+41 61 26 87122

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion